The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE

Gary E. Raskob, Alex C. Spyropoulos, Julie Zrubek, Walter Ageno, Gregory Albers, C. Gregory Elliott, Jonathan Halperin, Lloyd Haskell, William R. Hiatt, Gregory A. Maynard, Gary Peters, Theodore Spiro, Philippe Gabriel Steg, Eun Young Suh, Jeffrey I. Weitz

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


Hospital-associated venous thromboembolism (VTE) is a leading cause of premature death and disability worldwide. Evidence-based guidelines recommend that anticoagulant thromboprophylaxis be given to hospitalised medical patients at risk of VTE, but suggest against routine use of thromboprophylaxis beyond the hospital stay. The MARINER study is a randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of thromboprophylaxis using rivaroxaban, begun at hospital discharge and continued for 45 days, for preventing symptomatic VTE in high-risk medical patients. Eligible patients are identified using the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE VTE) risk score, combined with a laboratory test, D-dimer. The rivaroxaban regimen is 10 mg once daily for patients with CrCl ≥ 50 ml/min, or 7.5 mg once daily for patients with CrCl ≥ 30 ml/min and < 50 ml/ min. The primary efficacy outcome is the composite of symptomatic VTE (lower extremity deep-vein thrombosis and non-fatal pulmonary embolism) and VTE-related death. The principal safety outcome is major bleeding. A blinded clinical events committee adjudicates all suspected outcome events. The sample size is event-driven with an estimated total of 8,000 patients to acquire 161 primary outcome events. Study design features that distinguish MARINER from previous and ongoing thromboprophylaxis trials in medically ill patients are: (i) use of a validated risk assessment model (IMPROVE VTE) and D-dimer determination for identifying eligible patients at high risk of VTE, (ii) randomisation at the time of hospital discharge, (iii) a 45-day treatment period and (iv) restriction of the primary efficacy outcome to symptomatic VTE events.

Original languageEnglish
Pages (from-to)1240-1248
Number of pages9
JournalThrombosis and Haemostasis
Issue number6
StatePublished - 2016


  • Anticoagulants
  • Deep-vein thrombosis
  • Medical patients
  • Pulmonary embolism
  • Rivaroxaban
  • Thromboprophylaxis
  • Venous thromboembolism


Dive into the research topics of 'The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE'. Together they form a unique fingerprint.

Cite this